BRAF and neoplasm: For example, mutations in FGFR1, BRAF, RET, MET, HER-2 occur in about 3% of all NSCLC [21], and since tumours bearing these mutations were already successfully treated with targeted therapies in other types cancers, it has been hypothesised that they might be effective in NSCLC as well.